MAPK1 and cancer: We first examined whether an allosteric Shp2 inhibitor (Fig. 5A, RMC-4550: iShp2), which was initially developed to decouple the oncogenic Ras-to-Erk signaling in human cancers [21], inhibits LIF-dependent Erk activation.